Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
28.6 USD | -0.35% | +1.31% | -6.54% |
Mar. 25 | Arrowhead Pharmaceuticals, Inc. Initiates Expanded Access Program for Plozasiran | CI |
Mar. 08 | Arrowhead Doses First Subjects in Phase 1/2a Study of Myotonic Dystrophy Treatment; Shares Rise | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-6.54% | 3.54B | |
+2.73% | 108B | |
+9.59% | 103B | |
+6.58% | 23.48B | |
-12.59% | 21.93B | |
-3.29% | 19.68B | |
-35.36% | 18.37B | |
-13.29% | 16.33B | |
+4.68% | 13.72B | |
+34.25% | 12.15B |
- Stock
- Equities
- Stock Arrowhead Pharmaceuticals, Inc. - Nasdaq
- News Arrowhead Pharmaceuticals, Inc.
- Insider Trends: Arrowhead Pharmaceuticals Insider Sale Scales Back 90-Days of Buys